Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis.

BMC Cancer · 2026 · PMC13326477 · PMID 42151869

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Due to the limited sample size, the difference in survival between the two groups did not reach statistical significance.

also in 111,027 other papers

a suggestive trendno p-value reported

In between-intervention comparisons, nivolumab had HRs of 1.44 (95% CrI: 1.00-2.06) versus bevacizumab and 1.31 (95% CrI: 1.06–1.63) versus rindopepimut, indicating a suggestive trend of relatively poorer survival (Figure S3).

also in 203 other papers

a clear trendno p-value reported

In patients with recurrent GBM, while nivolumab demonstrated statistical significance compared to bevacizumab, the unmethylated subgroup exhibited a clear trend toward inferior survival (HR > 1, median OS 8.0 vs. 8.9 months).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.